Codelivery of Cell Apoptosis AVPIAQ Peptide and Doxorubicin for Synergistic Cancer Therapy
ACS Applied Bio Materials · 2025
DOI: 10.1021/acsabm.5c00607 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Bio Materials, 2025. Verfasst von Yonghui Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry, Tiangong University, Tianjin 300387, China. Hauptthemen laut MEDLINE: Doxorubicin, Apoptosis, Biocompatible Materials, Antineoplastic Agents. Die Arbeit nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemistry, Tiangong University, Tianjin 300387, China.
- School of Chemical Engineering and Technology, Tiangong University, Tianjin 300387, China.
ORCID-Profile: Jie Pan
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, Y., Ren, Z., Zhao, Y., Wan, D., & Pan, J. (2025). Codelivery of Cell Apoptosis AVPIAQ Peptide and Doxorubicin for Synergistic Cancer Therapy. ACS Applied Bio Materials. https://doi.org/10.1021/acsabm.5c00607
Vancouver
Liu Y, Ren Z, Zhao Y, Wan D, Pan J. Codelivery of Cell Apoptosis AVPIAQ Peptide and Doxorubicin for Synergistic Cancer Therapy. ACS Applied Bio Materials. 2025. doi:10.1021/acsabm.5c00607
BibTeX
@article{Liu2025,
author = {Liu, Yonghui and Ren, Zongqian and Zhao, Yu and Wan, Dong and Pan, Jie},
title = {Codelivery of Cell Apoptosis AVPIAQ Peptide and Doxorubicin for Synergistic Cancer Therapy},
journal = {ACS Applied Bio Materials},
year = {2025},
doi = {10.1021/acsabm.5c00607}
}
EUVIMED